Who is sponsoring NCT03461081?

NCT03461081 is sponsored by Jeil Pharmaceutical Co., Ltd..

What drugs are being tested in NCT03461081?

Interventions in NCT03461081: telmisartan/amlodipine and atorvastatin.

What condition does NCT03461081 study?

NCT03461081 studies Hypertension With Hyperlipidemia.

Is NCT03461081 still recruiting?

NCT03461081 is currently completed. Last updated 12 March 2018.

Last reviewed 2018-03-12 · How we verify

NCT03461081

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers

Completed Phase 1 Last updated 12 March 2018

What this trial tests

Phase 1 trial testing telmisartan/amlodipine and atorvastatin in Hypertension With Hyperlipidemia in 32 participants. Completed in 12 December 2017.

Timeline

7 May 2017

Primary endpoint
12 July 2017

12 December 2017

Quick facts

Lead sponsor	Jeil Pharmaceutical Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	7 May 2017
Primary completion	12 July 2017
Estimated completion	12 December 2017
Sites	1 location across South Korea

Drugs / interventions tested

telmisartan/amlodipine and atorvastatin — full drug profile →

Conditions studied

Hypertension With Hyperlipidemia — all drugs for Hypertension With Hyperlipidemia →

Sponsor

Jeil Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 19 to 55, male only, with Hypertension With Hyperlipidemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

study to evaluate drug-drug interaction following oral administration of telmisartan/amlodipine and atorvastatin in healthy adult volunteers

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Jeil Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07115706 — JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD · not yet recruiting
NCT06952855 — Observationa Study is a Prospective and Multi-institutional Observational Study. · completed
NCT06431399 — To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004 · Phase 1 · recruiting
NCT06169059 — To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004 · Phase 1 · completed
NCT06165965 — To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03461081 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jeil Pharmaceutical Co., Ltd.
Last refreshed: 12 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03461081.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing